Drug Information Association Logo

Joint DIA/ICOS Cardio-Oncology Conference

Oct 9 2014 8:00AM - Oct 10 2014 6:00PM | Dorint Praha Don Giovanni Hotel Vinohradská 157a 130 20 Prague Czech Republic

« Back to Listing

Overview 

There is a tremendous amount of mechanistic overlap between targeted cancer therapy and cardiovascular tissues.  Important drugs that may be active on cancerous tissues are increasingly likely to have significant collateral effects on cardiac tissues.  Understanding the underlying mechanisms and how to detect these problems early and manage them effectively can allow a critical drug for cancer efficacy to continue to develop as a clinical therapy. 

Additionally, tailoring the pharmacology of a potential cancer therapeutic based on known mechanistic insights is an essential area of preclinical development.  Furthermore, enhancing interactions between cardiology and oncology at all levels of clinical trials allows for optimal patient outcomes.

Who Should Attend 

  • Cardiology, oncology and primary care physicians, nurse practioners, and other allied providers
  • Drug development and clinical research managers and associates
  • Pharmacovigilance, drug safety and drug surveillance personnel
  • Pharmaceutical physicians and medical directors
  • Safety pharmacology and non-clinical scientists
  • Clinical pharmacology scientists
  • Regulatory affairs officers
  • Biostatisticians
  • Data managers
  • Outsourcing and marketing managers

Learning Objectives 

  • Describe the best methods of cardiotoxicity detection during early phase clinical trials
  • Understand the best management approaches to protecting cardiac tissues during aggressive cancer therapy
  • Detail known and theorised mechanistic actions of developing cancer therapy to allow cardioprotection
  • Establish and ensure effective communication between drug developers and prescribers
  • Promote optimal patient care between cardiology and oncology
          

Hotel & Travel 

Dorint Hotel Don Giovanni

Vinohradská 157a
13020 Prague
Czech Republic
+420 26703-1111
 
DIA has blocked a number of rooms at this hotel.
 
The hotel booking period will be open soon.
 

Contact Information 

For registration information please call DIA EMEA's Contact Centre on +41 61 225 51 51

For programme information please contact Sharon Evans Schuler: sharon.evans@diaeurope.org

For information on Exhibition please contact Roxann Schumacher:

 roxann.schumacher@diaeurope.org

DIA EMEA
Kuechengasse 16
4051 BASEL
SWITZERLAND

TEL.: +41 61 225 51 51
FAX: +41 61 225 51 52
E-MAIL: diaeurope@diaeurope.org

Program Committee 

Previous Next

Agenda  

Day 1 Thursday, Oct 09, 2014

  • 9:00AM - 10:00AM

    PRECLINICAL MODELS FOR ENSURING CARDIAC SAFETY


    Session Chair(s):

    • Boaz Mendzelevski, MD
      Vice President of Cardiology
      BioClinica Inc., United Kingdom
    • Krishna Prasad, MD, FRCP
      Manager, CV-Diabetes Unit/Consultant Cardiologist
      Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom

    In this sesison we will discuss the scope of toxicities and how they are documented.

    Speaker(s):

    • Cardiac Safety During Cancer Therapy: Clinical relevance and the scope of the problem
      Daniel J. Lenihan, DrMed, FACC
      Director, Cardiovascular Clinical Research; Prof, Div. Cardiovascular Medicine
      Vanderbilt University, United States
    • How Do We Detect Anticipated and Unanticipated Cardiac Toxicities in Early Phase Studies?
      Jacob Dupont
      Vice President of Clinical Research
      Oncomed Pharmaceuticals, Inc., United States
  • 11:00AM - 12:30PM

    DIRECT MYOCARDIAL TOXICITY, CARDIAC BIOMARKERS, AND DETECTING HEART FAILURE


    Session Chair(s):

    • Alexander Lyon
      Clinical Senior Lecturer in Heart Failure
      Imperial College London, United Kingdom
    • Daniela Cardinale
      Senior Deputy Director, Cardiology Unit
      European Institute of Oncology, Italy

    In this session we will disuss direct myocarcial toxicity and detection in the clinical arena

    Speaker(s):

    • Cancer Drug Development: Many potential targets can have cardiotoxicity
      Alexander Lyon
      Clinical Senior Lecturer in Heart Failure
      Imperial College London, United Kingdom
    • Role of Troponin and Natriuretic Peptides in Predicting and Preventing Cardiac Event in Cancer Patients
      Daniela Cardinale
      Senior Deputy Director, Cardiology Unit
      European Institute of Oncology, Italy
    • What Cut-Off for BNP Should We Have to Identify Risk for Heart Failure?
      Kenneth McDonald
      Associate Clinical Professor
      School Of Medicine & Medical Science, Ireland
  • 1:30PM - 3:00PM

    CARDIAC SAFETY IMAGING IN CLINICAL RESEARCH


    Session Chair(s):

    • Okan Ekinci
      Vice President Healthcare Consulting & Clinical Affairs
      Siemens Healthcare, Germany

    In this session the latest considerations for clinical imaging and cardiac safety will be highlighted.

    Speaker(s):

    • What are the Expectations for Optimal Echo Imaging?
      Daniel Rodriguez Munoz
      Cardiologist
      Ramon y Cajal University Hospital, Spain
    • How can MRI be Utilised Most Effectively?
      Okan Ekinci
      Vice President Healthcare Consulting & Clinical Affairs
      Siemens Healthcare, Germany
    • Are Nuclear Techniques Really Obsolete?
      Otto Lang
      Department of Nuclear Medicine
      Third Faculty of Medicine, Czech Republic
  • 3:30PM - 5:40PM

    CELLULAR SIGNALING AND LEFT VENTRICULAR DYSFUNCTION: TOXICITY MITIGATION OR THERAPEUTIC TREATMENT?


    Session Chair(s):

    • Giuseppe Curigliano
      European Institute of Oncology , Italy
    • Susan Dent
      Medical Oncologist, Founder
      Canadian Cardiac Oncology Network, Canada

    In this session the concept of translational research informing clinical practice will be introduced.

    Speaker(s):

    • How does Cardiotoxicity Affect our Cancer Treatment Choices?
      Giuseppe Curigliano
      European Institute of Oncology , Italy
    • Neuregulin: A classic ligand for myocardial protection?
      Anthony Caggiano
      Vice President Research & Development
      Acorda Therapeutics Inc., United States
    • Cardioprotection: Do we target the myocardium or the patient?
      Xavier Bosch
      Associate Professor of Medicine, Department of Cardiology
      Hospital Clinic, Spain

Day 2 Friday, Oct 10, 2014

  • 9:00AM - 10:30AM

    HYPERTENSION: SAFETY REQUIREMENTS AND TREATMENT


    Session Chair(s):

    • Ron Witteles
      Stanford University Medical Center, United States
    • Giuseppe Curigliano
      European Institute of Oncology , Italy

    How is hypertension an important safety issue in Oncology Trials?

    Speaker(s):

    • Oncology Drug-Induced Hypertension: An Overview
      Boaz Mendzelevski, MD
      Vice President of Cardiology
      BioClinica Inc., United Kingdom
    • How much of a Concern is there for HTN with Newer Targeted Cancer Therapy?
      Ron Witteles
      Stanford University Medical Center, United States
    • Case Presentation
      Daniel J. Lenihan, DrMed, FACC
      Director, Cardiovascular Clinical Research; Prof, Div. Cardiovascular Medicine
      Vanderbilt University, United States
  • 11:00AM - 12:30PM

    ARTERIAL / VENOUS THROMBOTIC EVENTS


    Session Chair(s):

    • Adam Torbicki
      Department of Pulmonary Circulation and Thromboembolic Diseases
      European Health Center / ICOS Eastern Europe, Poland

    In this session the complex interplay between thrombosis and anticoagulation in cancer patients will be described.

    Speaker(s):

    • Do We Have any Concerns about Arterial and Venous Thrombotic Events with Newer Agents?
      Giorgio Minotti
      Professor
      University Campus Bio-Medica Italy, Italy
    • What Is The Optimal Anticoagulation Strategy for Venous Thrombosis in Cancer Patients?
      Adam Torbicki
      Department of Pulmonary Circulation and Thromboembolic Diseases
      European Health Center / ICOS Eastern Europe, Poland
  • 2:00PM - 3:30PM

    Session 7: BIOSIMILARS: WHAT MUST WE EXPECT? POINT/COUNTERPOINT

    Speaker(s):

    • How Rigorous Should We Be to Establish Biosimilar Efficacy?
      Boaz Mendzelevski, MD
      Vice President of Cardiology
      BioClinica Inc., United Kingdom
    • Roadmap for Approving Generic or Biosimilar Antibiodies
      Krishna Prasad, MD, FRCP
      Manager, CV-Diabetes Unit/Consultant Cardiologist
      Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
  • 4:00PM - 5:40PM

    INTEGRATION AND COOPERATION-HOW DO WE ACHIEVE THIS?


    Session Chair(s):

    • Susan Dent
      Medical Oncologist, Founder
      Canadian Cardiac Oncology Network, Canada
    • Daniel J. Lenihan, DrMed, FACC
      Director, Cardiovascular Clinical Research; Prof, Div. Cardiovascular Medicine
      Vanderbilt University, United States

    In this session we will explore how to integrate cardiac safety into oncology research and practice.

    Speaker(s):

    • Cardiac Safety Assessment in Oncology Drug Development: Regulatory Involvement in International Collaborative Activities
      Colette Strnadova, PhD
      Senior Scientific Advisor
      Health Canada, Canada
    • How Do We Best Interact on Patient Care: An Oncologist point of view
      Susan Dent
      Medical Oncologist, Founder
      Canadian Cardiac Oncology Network, Canada

Exhibits  

Exhibition Opportunities Available!

Showcase your product or service to a truly global audience of qualified professionals, from entry level to expert, in the pharmaceutical, biotechnology, devices and related healthcare industries, government, academia and healthcare delivery.  

 

Download Application Form

 

For more information on exhibiting space and facilities, please contact Roxann Schumacher at DIA Europe on

+41 61 225 51 38 or email: Roxann.Schumacher@diaeurope.org

 

Registration Fees 

Member

Member Academia
€700.00
Member Government
€700.00
Standard
€1400.00

Non-Member

NonMember Academia
€830.00
NonMember Government
€830.00
NonMember Standard
€1530.00
Group Discounts

Group Discounts Available – Send 3 participants and the 4th is free!

Conditions apply. Online registration not available for group discounts. Call DIA in Europe on +41 61 225 51 51 or email for further information.

Register Online
« Back to Listing Back To Top